This clinical trial is focused on studying a condition known as Takotsubo syndrome, which is a temporary heart condition often triggered by stress. The study will evaluate the effectiveness of a medication called Cyclosporine A (also known as CsA) compared to a placebo. Cyclosporine A is a medication that is commonly used to prevent organ rejection after transplants and to treat certain inflammatory conditions.

The purpose of the study is to determine if Cyclosporine A can reduce heart muscle damage in patients with Takotsubo syndrome. Participants in the study will receive either Cyclosporine A or a placebo, in addition to their standard medical care. The study will monitor the levels of a specific protein in the blood, known as Troponin T, which is an indicator of heart muscle damage. This will help researchers understand if the treatment is effective in reducing damage to the heart.

Throughout the study, participants will undergo regular assessments to measure changes in their heart condition and overall health. These assessments will include monitoring Troponin T levels at various time points and evaluating heart function through imaging techniques. The study aims to provide valuable insights into the potential benefits of Cyclosporine A for patients with Takotsubo syndrome, with the hope of improving treatment options for this condition in the future.